Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Enliven Therapeutics, Inc.

Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights from clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. 

5AM Ventures

OrbiMed

Roche Venture Fund

Surveyor Capital

Boxer Capital

Janus Henderson Investors

Logos Capital

Cormorant Asset Management

Enliven Therapeutics

#DYK: Approximately 20% of people with CML switch therapy within the 1st year of treatment and up to 40% switch in the first 5 years of treatment. The majority of treatment switches occur early in the patient’s treatment course due to intolerance or lack and/or loss of molecular response. Join us on April 11th, to learn more about ELVN-001, our candidate for the treatment of CML: https://bit.ly/4cyFSP4

#DYK: Thanks to medical advancements, the number of patients living with #CML has more than doubled since the introduction of BCR-ABL TKIs, however, tolerability, safety, resistance and patient convenience concerns have become more prominent as patients can now expect to live on therapy for decades. Learn more: https://bit.ly/4afJ3cP 

We will be hosting a Virtual company event with KOLs on Thursday, 4/11, to discuss ELVN-001’s Phase 1a initial proof of concept data, the evolving treatment paradigm in #CML, and how ELVN-001 could fit into the CML landscape. Register here: https://bit.ly/4cyFSP4


#ICYMI: Yesterday we announced a $90M financing. We appreciate the support of our existing and new investors. This capital will help us continue to drive towards our goal of helping people with cancer to not only live longer, but live better. For more information, read the press release here: https://bit.ly/3TqPSkz 

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress. Learn more here: https://bit.ly/3Ve4whJ

msh id	COM:ENLIVENTHERAPEUTICS
symbol	ELVN
name	Enliven Therapeutics, Inc.
homepage url	https://www.enliventherapeutics.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	50
crunchbase url	-
linkedin url	-
founders	-

market cap	1.08B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	50.35
growth score 28	16.2
growth score 90	52.54
growth score 365	11.79

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

COM:ENLIVENTHERAPEUTICS

Enlivex Therapeutics Ltd.

Last Close

25.43

21/11 20:00

Market Cap

1.08B

Beta: -

Volume Today

64.73K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-